BTK and neoplasm: Interestingly, it has been shown that myeloid derived suppressor cells (MDSC) and other cells in the microenvironment also signal through BTK, the kinase inhibited by Ibrutinib, and the inhibition of this signaling pathway may enhance anti-tumor T cell responses, not only due to inhibition of B lymphocytes, but also other regulatory populations [42,43].